PAI Pharma

PAI Pharma acquires Nexus, adding 20+ hospital injectable products

Image
PAI Pharma acquires Nexus, adding 20+ hospital injectable products

PARSIPPANY, N.J. – November 12, 2026 -- PAI Pharma, a portfolio company of Olympus Partners, has acquired Nexus Pharmaceuticals, LLC, adding more than 20 hospital injectable products to its sterile injectable portfolio. The company announced the deal on November 12, 2026 and did not disclose the purchase price.

Nexus is the second sterile injectable acquisition PAI cites in the announcement. It follows the company's recent purchase of Nivagen, which brought aseptic manufacturing capabilities in Sacramento, California. PAI describes itself as a developer and manufacturer of oral liquid medicines and Ready-To-Use sterile injectable and hospital-focused products.